Summary
Conclusion
the dossier summarised in one paragraphThe computed 12-month bankruptcy probability of NPB Belgium is 4.3% (elevated). The 2025 annual accounts show equity of €5k and a net result of €-5k. Its solvency ranks better than 72% of 335 sector peers (fiscal year 2025). The company has been active since 2023 and the Belgian State Gazette contains no insolvency or warning signals.
Based on the State Gazette, CBE and 1 annual account.
Bankruptcy probability (12 mo)
Checked model v1 · free for everyone4.3%
Elevated
0%0,5%1,5%4%10%≥25%
Young company
+Higher-failure-rate region
+Annual accounts: weaker financial profile
+
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Trust signals
2 signalsYoung company
Founded in 2023, under 3 years, statistically higher risk.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.
Administrative Flags
No administrative flags
Financials
TurnoverNot published (abbreviated filing)
EBIT marginNot published (abbreviated filing)
Net result€-5k
Working capital€5k
Annual accounts & ratios
Source: NBB · 2025Annual accounts filed on 30-10-2025 with the NBB · fiscal year 2025 · verkort
Sector comparison
Fiscal year 2025 · NACE 46, Wholesale trade · compared within the same schema type (abbreviated schema)
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 62.9% | 35.1% | |
| Net result | €-5k | €42k | |
| Equity | €5k | €278k | |
| Gross operating margin | €-3k | €240k | |
| Total assets | €8k | €1.22M |
Median and position computed from NBB annual accounts filed by sector peers; own figures from the latest filed accounts.
| Fiscal year | 2025 |
|---|---|
| Revenue | - |
| EBITDA | - |
| Net profit | €-5k |
| Cash flow | - |
| Staff costs | - |
| Income taxes | - |
| Dividends | - |
| Total assets | €8k |
| Equity | €5k |
| Debt | €3k |
| of which ≤ 1y | €3k |
| of which > 1y | - |
| Working capital | €5k |
| Employees (FTE) | - |
Ratios (computed)
| 2025 | |
|---|---|
| Current ratio | 2.69 |
| Quick ratio | 2.69 |
| Working capital ratio | 62.9% |
| Solvency | 62.9% |
| Debt / equity | 0.59 |
| Long-term debt ratio | - |
| Interest coverage | - |
| Gross margin | - |
| Net margin | - |
| ROA | -61.0% |
| ROE | -97.0% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | 365d |
| Inventory turnover | - |
| Days inventory (DSI) | - |
Balance-sheet composition 2025
Full annual accounts
Filed balance sheet and income statement, exactly as deposited with the NBB.
| Line item | Code | 2025 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €8k |
| Current assets | 29/58 | €8k |
| Cash & bank | 54/58 | €8k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €8k |
| Equity | 10/15 | €5k |
| Contributions / capital | 10/11 | €10k |
| Accumulated profits (losses) | 14 | €-5k |
| Amounts payable | 17/49 | €3k |
| Amounts payable within one year | 42/48 | €3k |
| Trade debts payable within one year | 44 | €3k |
| Income statement | ||
| Gross operating margin | 9900 | €-3k |
| Operating result | 9901 | €-3k |
| Financial charges | 65 | €2k |
| Result before taxes | 9903 | €-5k |
| Net result for the period | 9904 | €-5k |
| Result to be appropriated | 9905 | €-5k |
Ratios computed by Checked.
Health barometer
FY 2025 · computed65
/ 100
Healthy
Computed from 3 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.
Unlock the full score breakdown, per-year score history and the indicative credit limit with Plus.
See plans →Computed by Checked from the NBB filing for FY 2025. Indicative, not credit advice.
Directors
Directors & mandates
3 directorsCurrent directors & mandates
-
Current09-02-2026 → present
-
Current26-07-2024 → present
-
Current15-03-2024 → present
Full appointment history from the Belgian State Gazette. Permanent representatives are shown for corporate directors.
Insolvency mandates
No insolvency mandates (liquidators, administrators) on record for this company.
Legal Structure
| NACE primary | Groothandel in farmaceutische en medische artikelen(46460) |
| Legal form | Private limited company(610) |
| Incorporation | 07-12-2023 |
| Status | Active |
| Postal code | 1000 |
Structure & network
Locations & real estate
Establishment units
1 locationNBP Belgium
since 20252.363.395.892
Physical sites registered in the Crossroads Bank for Enterprises (CBE).
Parcels1
Ground area1,027 m²
Buildings1
Building footprint800 m²
Volume (LiDAR)19,374 m³
Tallest building44.0 m · ±8 fl.
Real-estate footprint
Source: CBE × cadastre · address linkingParcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
Brussels
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21805E0534/00D000 | Brussels | 1,027 m² | 1 · 800 m² | 44.0 m · 8 fl. |
Methodology
via registered seat: 1
1 of 1 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Publications
Lifecycle & Insolvency Signals
No insolvency signals in the Belgian State Gazette
Belgian State Gazette · acts
2 verified actsWhat every Belgian State Gazette publication actually says, each act broken down into appointments, capital movements, seat moves and statute amendments.
2026
06-08-2026
Board meeting · Registered-office move
- Board meeting , 17/07/2026
- Registered-office move , Marnixlaan 23 (5de verdieping) 1000 Brussel België
23-03-2026
Resignations & appointments
- General meeting , 09/02/2026
- Director resignation, Ralf Parthoens (bestuurder)
- Director resignation, Christina Brunner (bestuurder)
- Director appointment, Hans de Raeve (bestuurder)
- Mandate compensation, Hans de Raeve
Analysis
Snowflake analysis
financial profile on 5 axes58
/ 100
Mixed profile: strong on solvency, weaker on profitability.
Computed on 4 of 5 axes. Not measured: growth. An unmeasured axis is not a zero: no data was read for it.
Health
65
Profitability
0
Solvency
99
Growth
-
Stability
67
Ask AI about this company
Checked AISoon: ask questions about this dossier, risks, curator, sector comparison, answered from the official data on this page.
TryWhat are the main risks?Any recent red flags?Compare to sector peers
Coming soonAI due-diligence brief
Checked AIGenerate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
Coming soon
The brief is drafted by our AI model at Anthropic in the US, from this dossier's public data. Nothing that identifies you is sent along and we do not keep the brief. Indicative, not legal or investment advice. How it works
Credit advice
verdict per customer and amountSimilar
Similar companies
Same sector, ranked by comparable sizeCompany registry
Company registry (CBE)
Crossroads BankActivities
Groothandel in farmaceutische en medische artikelen46460
Primary activity highlighted.
Names & trade names
| Legal nameNL | NPB Belgium |
Registered office
Marnixlaan 23
1000 Brussel, Belgium
Official data from the Crossroads Bank for Enterprises (CBE). Available for every registered company.